IL148031A0 - Torsemide polymorphs - Google Patents

Torsemide polymorphs

Info

Publication number
IL148031A0
IL148031A0 IL14803100A IL14803100A IL148031A0 IL 148031 A0 IL148031 A0 IL 148031A0 IL 14803100 A IL14803100 A IL 14803100A IL 14803100 A IL14803100 A IL 14803100A IL 148031 A0 IL148031 A0 IL 148031A0
Authority
IL
Israel
Prior art keywords
torsemide
polymorphs
torsemide polymorphs
Prior art date
Application number
IL14803100A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL148031A0 publication Critical patent/IL148031A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
IL14803100A 1999-08-11 2000-08-11 Torsemide polymorphs IL148031A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US18312700P 2000-02-17 2000-02-17
US21527300P 2000-06-30 2000-06-30
PCT/US2000/022081 WO2001010441A1 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Publications (1)

Publication Number Publication Date
IL148031A0 true IL148031A0 (en) 2002-09-12

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14803100A IL148031A0 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Country Status (24)

Country Link
US (1) US6465496B1 (hr)
EP (1) EP1207880A4 (hr)
JP (1) JP2003527319A (hr)
KR (1) KR20020025217A (hr)
CN (1) CN1378448A (hr)
AU (1) AU781461C (hr)
BG (1) BG106400A (hr)
CA (1) CA2379322A1 (hr)
CZ (1) CZ2002404A3 (hr)
DE (1) DE00957398T1 (hr)
ES (1) ES2204354T1 (hr)
HK (1) HK1046636A1 (hr)
HR (1) HRP20020120A2 (hr)
HU (1) HUP0204318A3 (hr)
IL (1) IL148031A0 (hr)
LT (1) LT5004B (hr)
MX (1) MXPA02001369A (hr)
NO (1) NO20020622L (hr)
PL (1) PL354262A1 (hr)
SI (1) SI20816A (hr)
SK (1) SK1912002A3 (hr)
TR (1) TR200200353T2 (hr)
WO (1) WO2001010441A1 (hr)
YU (1) YU9502A (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410802A1 (en) * 2000-02-17 2002-09-06 Minutza Leibovici A stable pharmaceutical formulation comprising torsemide modification ii
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (hr) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (hr) * 2002-07-19 2008-11-30 Pliva D.D. Novi postupak za pripravu modifikacije i n-(1-metiletilaminokarbonil)-4-(3-metilfenilamino)-3-piridinsulfonamida
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
US30633A (en) 1860-11-13 Improvement in fire-escapes
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
WO2001070226A1 (en) * 2000-03-20 2001-09-27 Teva Pharmaceutical Industries Ltd. Novel processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
LT2002017A (en) 2002-11-25
YU9502A (sh) 2005-06-10
HK1046636A1 (zh) 2003-01-24
AU6902600A (en) 2001-03-05
BG106400A (en) 2002-08-30
CZ2002404A3 (cs) 2002-06-12
NO20020622D0 (no) 2002-02-08
HUP0204318A3 (en) 2005-03-29
KR20020025217A (ko) 2002-04-03
CN1378448A (zh) 2002-11-06
LT5004B (lt) 2003-03-25
EP1207880A1 (en) 2002-05-29
HUP0204318A2 (en) 2003-05-28
WO2001010441A1 (en) 2001-02-15
AU781461B2 (en) 2005-05-26
MXPA02001369A (es) 2005-08-26
TR200200353T2 (tr) 2002-06-21
SK1912002A3 (en) 2002-07-02
PL354262A1 (en) 2003-12-29
ES2204354T1 (es) 2004-05-01
SI20816A (sl) 2002-08-31
DE00957398T1 (de) 2004-04-15
JP2003527319A (ja) 2003-09-16
HRP20020120A2 (en) 2003-10-31
EP1207880A4 (en) 2004-09-01
CA2379322A1 (en) 2001-02-15
NO20020622L (no) 2002-03-14
AU781461C (en) 2006-02-23
US6465496B1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
EG23817A (en) 4-Phenyl-pyridine derivatives
GC0000183A (en) 3-Phenyl-pyridine derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
IL148031A0 (en) Torsemide polymorphs
EG23070A (en) Novel propargylether derivatives
HK1044940A1 (zh) 異噁唑咪唑羧酰胺衍生物
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
HUP0300241A3 (en) Processes for preparing torsemide intermediate
GB0026485D0 (en) ›-Carboline derivatives
HUP0204217A3 (en) Novel a-500359 derivatives
HK1045987A1 (zh) 3-氨基-2-苄基-1-苯基-丙烷衍生物
HK1048638A1 (zh) Cyclopenteneone衍生物
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
AP2001002327A0 (en) 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
IL154457A0 (en) Mircronized torsemide
GB9921851D0 (en) Structural elements
GB0027081D0 (en) Solution
GB2357543B (en) Structural members
TW433433U (en) Improved lampstand
AU2790P (en) Diamante Fragaria xananassa
AU1555P (en) Maroochy Sundew Fragaria xananassa
AU2789P (en) Gaviota Fragaria xananassa
TW453269U (en) Improved structure for bow-saw
TW386346U (en) Improved dovecote
AU137034S (en) Blouse